HomeOwner SearchCategory Search
Visit USCONovel Immunotherapy Agents in Oncology: Generalizability of Trial Results and Drivers of Clinical Utilization
![hero image](/_next/image?url=%2Fimages%2FCRLogo.png&w=384&q=75)
Text Registration
Copyright Title
Novel Immunotherapy Agents in Oncology: Generalizability of Trial Results and Drivers of Clinical Utilization
Status
Published
on 9 Sept 2021
Year of Creation
2021
Copyright Claimant
Grace Mishkin
Registration Number
TX0009010597
on 9 Sept 2021Copyright Summary
The U.S. Copyright record (Registration Number: TX0009010597) dated 9 Sept 2021, pertains to an electronic file (eService) titled "Novel Immunotherapy Agents in Oncology: Generalizability of Trial Results and Drivers of Clinical Utilization" created in 2021. The copyright holder is Grace Mishkin, known for their creative contributions in text registration. For any inquiries concerning this copyrighted material, kindly reach out to Grace Mishkin.
Application Details
Registration Number
TX0009010597
Registration Date
9/9/2021
Year of Creation
2021
Agency Marc Code
DLC-CO
Record Status
New
Physical Description
Electronic file (eService)
First Publication Nation
United States
Notes
Rights Note: Mark Dill, ProQuest, LLC, 789 E. Eisenhower Parkway, Ann Arbor, MI, 48108-3218, United States, (800) 521-0600, disspub@proquest.com
Statements
Application Title Statement: Novel Immunotherapy Agents in Oncology: Generalizability of Trial Results and Drivers of Clinical Utilization
Author Statement: Grace E. Mishkin Citizenship: not known Authorship: text
© 2024 reserved by Trademarkia
Show terms & conditions
Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal advice. Although LegalForce RAPC Worldwide P.C., dba Trademarkia P.C., is a law firm (the “Firm”), your use of this website does not establish an attorney-client relationship with the Firm. Such a relationship can only be established after the Firm decides that it is willing and able to accept the engagement after a conflict check and after a written retainer agreement is agreed upon between you and the Firm. Your use of this website is also subject to our Terms of Use and Privacy Policy. ** The entry level subscription is a bundled price which requires a minimum of two billing cycles, or 6 months.